Charles Schwab Investment Management Inc Caladrius Biosciences, Inc. Transaction History

Charles Schwab Investment Management Inc

  • $515 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021
SELL
$1.4 - $1.9 $28,820 - $39,113
-20,586 Closed
0 $0
Q1 2021

May 17, 2021
BUY
$1.44 - $2.89 $29,643 - $59,493
20,586 New
20,586 $40,000

About CALADRIUS BIOSCIENCES, INC.

CLBS Quotes by TradingView
  • Ticker CLBS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,583,200
  • Market Cap $25.8M
  • Description
  • Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical li...
More about CLBS
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email